For decades, the digital rectal exam (DRE), the traditional “finger test,” has been a routine component of prostate screening. It is quick, inexpensive, and engrained in medical culture. But the question is no longer whether we can do it. It is whether we should. With PSA testing, advanced imaging, and refined risk stratification, routine DRE in asymptomatic men is increasingly indefensible.
Low sensitivity and limited value
Recent studies show that DRE has poor sensitivity and specificity for clinically significant prostate cancer. A 2023 report concluded that DRE is not a useful screening test for prostate cancer. In a 2024 analysis, only 3 percent of men with abnormal DRE but normal PSA were found to have clinically significant cancer. A 2025 review emphasized the diminishing role of DRE in modern diagnostic pathways. Contemporary guidelines from the AUA/SUO also state that DRE should not be used as the sole screening method in asymptomatic men.
Psychological and behavioral impact
Beyond diagnostic limitations, routine DRE may reduce patient engagement with care. Many men report embarrassment, anxiety, or feelings of violation, which can deter future screening or conversations about prostate health. A procedure that is low-yield but potentially distressing undermines trust and may reduce uptake of preventive services.
Superior alternatives exist
PSA testing, risk calculators, biomarkers, and multiparametric MRI now provide higher diagnostic efficacy and more nuanced risk assessment. These tools are quantitative, reproducible, and patient-centered, unlike DRE, which is subjective and highly operator-dependent. Current evidence suggests that these alternatives replace DRE in initial screening for asymptomatic men.
When DRE remains appropriate
DRE is still valuable in symptom-driven evaluation: men with urinary retention, rectal bleeding, pelvic pain, or imaging abnormalities. In these contexts, DRE is diagnostic, not screening. But these situations do not justify its routine use in asymptomatic populations.
Recommendations for clinicians and guideline bodies
- Eliminate routine DRE in asymptomatic men; rely on PSA and validated risk-stratification tools.
- Emphasize training and shared decision-making: Teach clinicians the proper, respectful use of DRE for symptom-driven evaluation.
- Update screening guidelines to reflect evidence that DRE is not required for population-based prostate cancer screening.
- Maintain equity and access: Ensure high-risk populations continue to receive PSA testing, biomarkers, and imaging as needed.
In conclusion, medicine should prioritize both high scientific standards and patient dignity. Continuing routine DRE in asymptomatic men is low-yield, potentially traumatizing, and unnecessary. By retiring the finger test for screening and adopting modern, evidence-based pathways, we improve diagnostic accuracy, reduce patient discomfort, and align care with contemporary standards.
Paul Dranichnikov is a physician in Sweden.
